1,721,720 research outputs found
Cardio-metabolic comorbidities in patients with psoriasis
No full textFil: Cozzi, Alessandra. University of Verona. Department of Medicine. Section of Dermatology and Venereology; ItalyFil: Gisondi, Paolo. University of Verona. Department of Medicine. Section of Dermatology and Venereology; ItalyFil: Girolomoni, Giampiero. University of Verona. Department of Medicine. Section of Dermatology and Venereology; Ital
Il valore della terapia topica in dermatologia
No full textil valore della terapia topica in dermatologi
Hidradenitis suppurativa: an emerging debilitating disease with new and effective therapeutic options
No full textHidradenitis suppurativa (HS) is a chronic inflammatory disease manifesting with painful, deep abscesses and chronic, draining sinus tracts
typically in young patients. HS remains widely unrecognized and difficult to treat, resulting in significant diagnostic delay and inconsistent treatment process. HS is associated with metabolic changes including obesity, metabolic syndrome and diabetes. HS is the results of an inappropriate inflammatory response following hair follicle occlusion and rupture, and can be part of the clinical spectrum of pyogenic auto-inflammatory
syndromes. Treatments used in the management of this condition remain off-label. Traditional therapies, such as systemic antibiotics, retinoids,
immunosuppressants, and antiandrogens all have been used with limited success. Among biological treatments, adalimumab given weekly and infliximab are effective for HS. Surgery is an important option but recurrence or disfiguring results are commo
The efficacy and safety of topical pimecrolimus in pediatric patients with atopic dermatitis.
No full textPimecrolimus is a calcineurin inhibitor developed for the topical treatment of atopic dermatitis. It selectively targets T cells and mast cells, but since it has no effects on dendritic cells, endothelial cells and fibroblasts, it does not induce skin atrophy. Pimercolimus was effective, well-tolerated and safe in infants, children and adolescents with mild to moderate atopic dermatitis in several randomized control trials. Given the low capacity of the drug to permeate through the skin, there is no evidence of systemic immunosuppression from topical pimecrolimus therapy
Impact of TNF-α antagonists on the quality of life in selected skin diseases
No full textVengono riassunte le implicazioni sulla qualità della vita di malattie infiammatorie dermatologiche, e l'efficacia della terapia con farmaci anti-TNF alpha su parametri correlati con la qualità di vit
Psoriasis and systemic inflammation: underdiagnosed enthesopathy
No full textOur understanding of the pathogenesis of psoriasis is changing rapidly and the traditional view that it is a disease limited to the skin continues to be challenged. Indeed, there is convincing evidence that psoriasis patients have a higher prevalence of comorbid disease, particularly cardio-metabolic disorders and psoriatic arthritis (PsA). The results of recent investigations into psoriasis and cardiovascular or metabolic comorbidities provide increasing evidence for a possible shared pathogenic mechanism for these disorders, linked by an underlying chronic systemic inflammatory state. This highlights the importance of investigating associated comorbidities beyond skin manifestations. Psoriatic arthritis is a chronic inflammatory arthropathy that can occur in association with psoriasis and most commonly affects the distal joints in the hands and feet. Skin lesions precede arthritic symptoms in approximately 75% of cases; typically, the cutaneous manifestations of the disease develop 10 years prior to the onset of joint symptoms. This disease course, therefore, provides a potential window of opportunity to initiate effective and aggressive therapies to prevent long-term damage, if symptoms of PsA can be detected early. One of the major features of PsA is enthesitis, yet clinically asymptomatic cases of entheseal abnormalities are likely to go undiagnosed. This concept was evaluated in a prospective study in which entheseal changes in clinically asymptomatic psoriasis patients were compared with findings from a control group. Ultrasonography detected a significantly higher incidence of entheseal abnormalities in patients with psoriasis, despite the absence of clinical symptoms of arthropathy. Ongoing monitoring of these patients has also revealed that a higher baseline score for enthesitis may be associated with a more severe psoriasis outcome. These findings demonstrate that detecting early signs of PsA in asymptomatic patients with psoriasis may have the potential to positively influence disease prognosis and ultimately clinical outcome. Dermatologists can, therefore, play a key role in the early detection and management of PsA
Glomerular filtration rate in patients with psoriasis treated with etanercept
No full textObjective: To estimate the prevalence of chronic kidney disease (CKD) and evaluate renal function in patients with moderate-to-severe chronic plaque psoriasis treated with etanercept (an anti-tumour necrosis factor-a drug). Methods: This retrospective cohort study included patients with moderate-to-severe chronic plaque psoriasis. Kidney function was evaluated using estimated glomerular filtration rate (EGFR). Results: The prevalence of CKD at baseline was 3.9% (two of 51 patients). EGFR was unaffected by etanercept therapy (83.623.9 at baseline vs 82.221.6 ml/min per 1.73m2 after 6 months). Conclusion: EGFR was unaffected by 6 months’ etanercept treatment. Physicians should be aware of the risk of CKD when providing comprehensive care to patients with moderate-to-severe psoriasi
- …
